Pharma Executive: Dr. Malpani, I’ve been thinking a lot about how we can better engage with doctors and patients. The old model of sending medical representatives (MRs) to clinics is becoming increasingly ineffective. Doctors just don’t have the time for it anymore.
Dr. Malpani: You’re absolutely right. The healthcare landscape is changing rapidly. Doctors are overwhelmed, and their schedules are packed. Expecting them to carve out time for long MR visits feels outdated. But I believe AI-powered doctor replicas can solve this problem in a way that benefits everyone—pharma companies, doctors, and most importantly, patients.
Pharma Executive: AI replicas? That sounds intriguing, but how would that work in the context of pharma?
Dr. Malpani: Imagine having a 24/7 AI video chatbot that serves as the medical face of your company. This AI replica would act as a scientific advisor for doctors. It could answer questions about your products, explain mechanisms of action, discuss indications and side effects, and even offer guidance on drug interactions—all in real-time.
Pharma Executive: I love the idea of 24/7 availability. One of the biggest challenges we face is that doctors need information on their own schedule, not during a brief MR visit. But wouldn’t doctors still prefer talking to a human?
Dr. Malpani: Not necessarily. What doctors value most is convenience and accuracy. If they can get reliable, evidence-based answers at midnight or between patient appointments without waiting for an MR, they’ll take it. The AI can replicate the tone and expertise of your best medical experts, providing consistent, unbiased information.
Pharma Executive: But won’t AI lack the nuance that a human expert can provide, especially when it comes to complex medical questions?
Dr. Malpani: That’s a common concern, but AI has come a long way. These replicas are trained on the latest research and continuously updated, unlike some MRs who may still be working off outdated slides. If a question goes beyond the AI’s knowledge base, it can flag the query for a follow-up from a live expert. This ensures accuracy without creating bottlenecks.
Pharma Executive: I can see how that could free up our human resources for more critical engagements. But how would this AI system handle personalization? Different doctors have different needs and preferences.
Dr. Malpani: AI excels at personalization. Over time, the AI chatbot learns from each interaction, tailoring its responses based on the doctor’s specialty, practice patterns, and interests. For example, a cardiologist might receive in-depth information on lipid-lowering drugs, while a general practitioner gets broader insights on managing hypertension.
Pharma Executive: That could make our interactions far more meaningful. But how would this affect patient engagement? We’re not just focused on doctors; we want patients to trust and understand our products too.
Dr. Malpani: That’s another area where AI shines. You can create patient-facing AI replicas as well, that explain medications in simple terms—dosage, side effects, and what to expect. These can be embedded on your website or even integrated into patient portals. It builds trust and reduces the risk of medication errors.
Pharma Executive: This could be a game-changer for patient education. But what about feedback loops? One of the valuable aspects of MR visits is getting insights from doctors about what’s working and what isn’t.
Dr. Malpani: AI can facilitate that as well. The chatbot can prompt doctors for feedback after consultations—questions like “How do you feel about this product?” or “What could we improve?” This feedback is instantly analyzed, allowing your team to identify trends and act quickly. Over time, this creates a continuous improvement cycle.
Pharma Executive: That could make us far more responsive to market needs. I imagine this kind of AI engagement would also help us stand out from other pharma companies.
Dr. Malpani: Absolutely. Healthcare is becoming more competitive, and doctors are bombarded with information from countless pharma companies. Offering round-the-clock AI access positions you as an innovator. Doctors will gravitate toward companies that respect their time and provide on-demand, valuable insights.
Pharma Executive: But what about the regulatory side? Pharma is highly regulated, and we must ensure that everything we communicate is compliant.
Dr. Malpani: That’s the beauty of AI. Every interaction is documented and traceable. You have a complete record of what the AI said, which ensures compliance and reduces risk. Plus, AI won’t stray from approved guidelines or make unsubstantiated claims—it will strictly adhere to evidence-based information.
Pharma Executive: That’s reassuring. I imagine this could also help reduce the risk of litigation. If there’s ever a dispute, we have a full digital trail.
Dr. Malpani: Exactly. AI adds an additional layer of transparency and accountability. It ensures that doctors and patients receive consistent, accurate messaging without the variability that can sometimes occur with human representatives.
Pharma Executive: I can see how this could become an invaluable marketing tool. Not only are we providing innovative technology, but we’re also enhancing the doctor-patient relationship by giving them more access to reliable information.
Dr. Malpani: And that’s the ultimate goal—better patient outcomes. When doctors are well-informed and confident in the medications they prescribe, it leads to higher adherence rates and better results for patients. This builds trust in your brand and ultimately drives long-term success.
Pharma Executive: I’m sold. How do we get started with this?
Dr. Malpani: Start with a pilot program—perhaps with one or two products. Develop the AI chatbot, train it thoroughly, and launch it with a select group of doctors. Collect feedback, refine the process, and scale it gradually. Before you know it, this AI replica could become your most valuable asset.
Pharma Executive: Thank you, Dr. Malpani. This sounds like the future of pharma engagement.
Dr. Malpani: My pleasure. If you’re ready to lead the way in pharma innovation on integrating AI into healthcare.